Terms: = Uterine cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
79 results:
1. cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
2. Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
Filipas DK; Labban M; Beatrici E; Stone BV; Qian Z; D Andrea V; Ludwig TA; Reis LO; Cole AP; Trinh QD
Vaccine; 2024 Jan; 42(3):441-447. PubMed ID: 38184391
[TBL] [Abstract] [Full Text] [Related]
3. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract] [Full Text] [Related]
4. T cell immunotherapy for cervical cancer: challenges and opportunities.
Yu L; Lanqing G; Huang Z; Xin X; Minglin L; Fa-Hui L; Zou H; Min J
Front Immunol; 2023; 14():1105265. PubMed ID: 37180106
[TBL] [Abstract] [Full Text] [Related]
5. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract] [Full Text] [Related]
6. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.
Zheng X; Gu H; Cao X; Pan B; Xiang H; Ju M; Xu S; Zheng M
Front Immunol; 2023; 14():1113369. PubMed ID: 36875089
[TBL] [Abstract] [Full Text] [Related]
7. Highlights into historical and current immune interventions for cancer.
Cole K; Al-Kadhimi Z; Talmadge JE
Int Immunopharmacol; 2023 Apr; 117():109882. PubMed ID: 36848790
[TBL] [Abstract] [Full Text] [Related]
8. Generation and Functional Characterization of PLAP car-T Cells against Cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
9. Factors associated with cervical cancer screening among women aged 25-60 years in Lao People's Democratic Republic.
Phaiphichit J; Paboriboune P; Kunnavong S; Chanthavilay P
PLoS One; 2022; 17(4):e0266592. PubMed ID: 35390098
[TBL] [Abstract] [Full Text] [Related]
10. Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical cancer.
Jiang Y; Gu H; Zheng X; Pan B; Liu P; Zheng M
Pathol Oncol Res; 2021; 27():1609946. PubMed ID: 34992504
[No Abstract] [Full Text] [Related]
11. Expression profiling of lncRNAs and mRNAs in placental site trophoblastic tumor (PSTT) by microarray.
Gan J; Chen Z; Feng X; Wei Z; Zhang S; Du Y; Xu C; Zhao H
Int J Med Sci; 2022; 19(1):1-12. PubMed ID: 34975294
[TBL] [Abstract] [Full Text] [Related]
12. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.
Pestana RC; Roszik J; Groisberg R; Sen S; Van Tine BA; Conley AP; Subbiah V
Curr Probl Cancer; 2021 Oct; 45(5):100794. PubMed ID: 34656365
[TBL] [Abstract] [Full Text] [Related]
13. The Asian perspective on HIFU.
Lee KW
Int J Hyperthermia; 2021 Sep; 38(2):5-8. PubMed ID: 34420444
[TBL] [Abstract] [Full Text] [Related]
14. Is stress related to the presence and persistence of oncogenic human papillomavirus infection in young women?
Kuebler U; Fischer S; Mernone L; Breymann C; Abbruzzese E; Ehlert U
BMC Cancer; 2021 Apr; 21(1):419. PubMed ID: 33863301
[TBL] [Abstract] [Full Text] [Related]
15. High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy.
Taguchi A; Nakajima Y; Furusawa A; Yoshino Y; Takao M; Kashiyama T; Kino N; Yasugi T
J Obstet Gynaecol Res; 2021 May; 47(5):1862-1870. PubMed ID: 33611808
[TBL] [Abstract] [Full Text] [Related]
16. Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis.
Raffone A; Seracchioli R; Raimondo D; Maletta M; Travaglino A; Raimondo I; Giaquinto I; Orsini B; Insabato L; Pellicano M; Zullo F
Arch Gynecol Obstet; 2021 Jan; 303(1):47-53. PubMed ID: 33098006
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
Han X; Liu S; Yang G; Hosseinifard H; Imani S; Yang L; Maghsoudloo M; Fu S; Wen Q; Liu Q
Gynecol Oncol; 2021 Jan; 160(1):351-360. PubMed ID: 33092868
[TBL] [Abstract] [Full Text] [Related]
18. Novel cellular immunotherapy using NKG2D car-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract] [Full Text] [Related]
19. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells.
He Y; Li XM; Yin CH; Wu YM
J Reprod Immunol; 2020 Jun; 139():103115. PubMed ID: 32199196
[TBL] [Abstract] [Full Text] [Related]
20. cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung cancer Antigen-1.
Marcinkowski B; Stevanović S; Helman SR; Norberg SM; Serna C; Jin B; Gkitsas N; Kadakia T; Warner A; Davis JL; Rooper L; Hinrichs CS
J Immunother Cancer; 2019 Aug; 7(1):229. PubMed ID: 31455429
[TBL] [Abstract] [Full Text] [Related]
[Next]
